In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Drugs Will Continue To Command High Prices, Scully Predicts

Executive Summary

The transformation in the Medicare market will not prevent cancer drugs from commanding very high prices, former Centers for Medicare & Medicaid Services Administrator Tom Scully predicted during the Washington Research Group's annual symposium Nov. 5

You may also be interested in...



Targeted Oncologics Will Sustain High Prices With Clear Benefits, GSK Says

The high price tags of targeted therapies will continue to be supported as specific populations are identified where the oncologics can show a clear benefit, according to GlaxoSmithKline Chairman of R&D Tachi Yamada

Targeted Oncologics Will Sustain High Prices With Clear Benefits, GSK Says

The high price tags of targeted therapies will continue to be supported as specific populations are identified where the oncologics can show a clear benefit, according to GlaxoSmithKline Chairman of R&D Tachi Yamada

Rx Industry Must Change “Mission” To Prepare For Medicare – Scully

The Medicare prescription drug benefit that begins in 2006 will fundamentally change the mission of pharmaceutical companies, former Centers for Medicare & Medicaid Services Administrator Tom Scully told the Washington Research Group's annual symposium in Washington, D.C. Nov. 5

Related Content

UsernamePublicRestriction

Register

PS044958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel